| 1 |
Durand ML. Bacterial and fungal endophthalmitis[J]. Clin Microbiol Rev, 2017, 30(3): 597-613.
|
| 2 |
Ly V, Sallam A. Fungal endophthalmitis[M]. Treasure Island (FL): StatPearls Publishing, 2021.
|
| 3 |
Durand ML. Endophthalmitis // Mandell GL, Bennett JE, Dolin R. Mandell, Douglas, and Bennett′s principles and practice of infectious diseases[M]. 8th ed. Philadelphia: W．B. Saunders, 2015：1415-1422.
|
| 4 |
Sridhar J, Flynn HW Jr, Kuriyan AE, et al. Endogenous fungal endophthalmitis: risk factors, clinical features, and treatment outcomes in mold and yeast infections[J]. J Ophthalmic Inflamm Infection, 2013, 3(1): 60.
|
| 5 |
Moloney TP, Park J. Microbiological isolates and antibiotic sensitivities in culture-proven endophthalmitis: a 15-year review[J]. Br J Ophthalmol, 2014, 98(11)：1492-1497.
|
| 6 |
Vaziri K, Schwartz SG, Kishor K, et al. Endophthalmitis: state of the art[J]. Clin Ophthalmol, 2015, 9: 95-108.
|
| 7 |
Rota N, Danese C, Menchini F, et al. Fungal endogenous endophthalmitis secondary to magnusiomyces capitatus[J]. Case Rep Ophthalmol, 2019, 10(2): 292-298.
|
| 8 |
Regan KA, Radhakrishnan NS, Hammer JD, et al. Endogenous endophthalmitis: yield of the diagnostic evaluation[J]. BMC Ophthalmol, 2020, 20(1)：1-7.
|
| 9 |
Kasper DL, Fauci AS. 哈里森感染病学[M]. 胡必杰，潘珏，高晓东，译. 上海：上海科学技术出版社，2019.
|
| 10 |
Gruener AM, Allen F, Stanford MR, et al. Aspergillus fumigatus endophthalmitis with necrotizing scleritis following pars plana vitrectomy[J]. Case Rep Ophthalmol Med, 2016: 9289532.
|
| 11 |
许迅. 我国眼底病研究发展现状、进展和努力方向[J]. 中华眼科杂志，2014，50(11): 808-813.
|
| 12 |
Lin CJ, Chen WL, Lin JM, et al. Endogenous endophthalmitis caused by Cryptococcus neoformans var. gattii mimicking choroidal tumor: from positron-emission tomography/computed tomography to histopathology[J]. Indian J Ophthalmol, 2017, 65(6): 526-528.
|
| 13 |
Spadea L, Giannico MI. Diagnostic and management strategies of aspergillus endophthalmitis: current insights[J]. Clin Ophthalmol, 2019, 13: 2573-2582.
|
| 14 |
Milligan AL, Gruener AM, Milligan ID, et al. Isolated endogenous Fusarium endophthalmitis in an immunocompetent adult after a thorn prick to the hand[J]. Am J Ophthalmol Case Rep, 2017, 6: 45-47.
|
| 15 |
Verweij PE, Mennink-Kersten MASH. Issues with galactomannan testing[J]. Med Mycol, 2006, 44(S1): S179-S183.
|
| 16 |
Fortun J, Martin-Davila P, Alvarez ME, et al. Aspergillus antigenemia sandwich-enzyme immunoassay test as a serodiagnostic method for invasive aspergillosis in liver transplant recipients[J]. Transplantation, 2001, 71(1): 145-149.
|
| 17 |
Patterson TF, Thompson GR 3rd, Denning DW, et al. Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America[J]. Clin Infect Dis, 2016, 63(4): e1-e60.
|
| 18 |
Clancy CJ, Jaber RA, Leather HL, et al. Bronchoalveolar lavage galactomannan in diagnosis of invasive pulmonary aspergillosis among solid-organ transplant recipients[J]. J Clin Microbiol, 2007, 45(6): 1759-1765.
|
| 19 |
中国医药教育协会感染疾病专业委员会. 抗菌药物药代动力学/药效学理论临床应用专家共识[J]. 中华结核和呼吸杂志，2018, 41(6): 409-446.
|
| 20 |
Felton T, Troke PF, Hope WW. Tissue penetration of antifungal agents[J]. Clin Microbiol Rev, 2014, 27(1): 68-88.
|
| 21 |
Lestrade PP, Bentvelsen RG, Schauwvlieghe AFAD, et al. Voriconazole resistance and mortality in invasive aspergillosis: a multicenter retrospective cohort study[J]. Clin Infect Dis, 2019, 68(9): 1463-1471.
|
| 22 |
Zarrin M, Faramarzi S. Study of azole - resistant and Cyp51a gene in aspergillus fumigatus[J]. Open Access Maced J Med Sci, 2018, 6(5): 747-750.
|
| 23 |
Howard SJ, Cerar D, Anderson MJ, et al. Frequency and evolution of azole resistance in aspergillus fumigatus associated with treatment failure[J]. Emerg Infect Dis, 2009, 15(7): 1068-1076.
|
| 24 |
Clinical and Laboratory Standards Institute. Epidemiological cutoff values for antifungal susceptibility testing[R]. 3rd ed. Wayne, PA: CLSI, 2020.
|
| 25 |
Dean L. Voriconazole therapy and CYP2C19 genotype // Pratt VM, McLeod HL, Dean L, et al. Medical genetics summaries[M]. Bethesda: National Center for Biotechnology Information, 2012.
|
| 26 |
Moriyama B, Obeng AO, Barbarino J, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy[J]. Clin Pharmacol Ther, 2017, 102(1): 45-51.
|
| 27 |
Weishaar PD, Flynn HW Jr, Murray TG, et al. Endogenous Aspergillus endophthalmitis. Clinical features and treatment outcomes[J]. Ophthalmology, 1998, 105(1)：57-65.
|
| 28 |
Sallam A, Taylor SR, Khan A, et al. Factors determining visual outcome in endogenous Candida endophthalmitis[J]. Retina, 2012, 32(6): 1129-1134.
|